Abstract
The amyloid β-peptide (Aβ) plays an early and critical role in the pathogenic cascade leading to Alzheimers disease (AD). Aβ is typically found in extracellular amyloid plaques that occur in specific brain regions in the AD and Down syndrome brain. Mounting evidence, however, indicates that intraneuronal accumulation of this peptide may also contribute to the cascade of neurodegenerative events that occur in AD and Down syndrome. A pathogenic role for intracellular Aβ is not without precedent, as it is known to be an early and integral component of the human muscle disorder inclusion body myositis (IBM). Therefore, it is plausible that intracellular Aβ may likewise induce cytopathic effects in the CNS, causing neuronal and synaptic dysfunction and perhaps even neuronal loss. Here we review recent evidence supporting a pathogenic role for intracellular Aβ in AD, Down syndrome, and IBM.
Keywords: parkinsons disease, amyotrophic lateral sclerosis, amyloid plaques, inclusion body myositis, alzheimers disease, paired helical filaments, brain
Current Alzheimer Research
Title: Amyloid β-Peptide: The Inside Story
Volume: 1 Issue: 4
Author(s): Bertrand P. Tseng, Masashi Kitazawa and Frank M. LaFerla
Affiliation:
Keywords: parkinsons disease, amyotrophic lateral sclerosis, amyloid plaques, inclusion body myositis, alzheimers disease, paired helical filaments, brain
Abstract: The amyloid β-peptide (Aβ) plays an early and critical role in the pathogenic cascade leading to Alzheimers disease (AD). Aβ is typically found in extracellular amyloid plaques that occur in specific brain regions in the AD and Down syndrome brain. Mounting evidence, however, indicates that intraneuronal accumulation of this peptide may also contribute to the cascade of neurodegenerative events that occur in AD and Down syndrome. A pathogenic role for intracellular Aβ is not without precedent, as it is known to be an early and integral component of the human muscle disorder inclusion body myositis (IBM). Therefore, it is plausible that intracellular Aβ may likewise induce cytopathic effects in the CNS, causing neuronal and synaptic dysfunction and perhaps even neuronal loss. Here we review recent evidence supporting a pathogenic role for intracellular Aβ in AD, Down syndrome, and IBM.
Export Options
About this article
Cite this article as:
Tseng P. Bertrand, Kitazawa Masashi and LaFerla M. Frank, Amyloid β-Peptide: The Inside Story, Current Alzheimer Research 2004; 1 (4) . https://dx.doi.org/10.2174/1567205043332045
DOI https://dx.doi.org/10.2174/1567205043332045 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Catatonia, Malignant Catatonia, and Neuroleptic Malignant Syndrome
Current Psychiatry Reviews Systemic Lupus Erythematosus-Related Interstitial Lung Disease
Current Rheumatology Reviews The Proteasome in Health and Disease
Current Pharmaceutical Design Disaggregating Chaperones: An Unfolding Story
Current Protein & Peptide Science Multiscale Modelling of Relationships between Protein Classes and Drug Behavior Across all Diseases Using the CANDO Platform
Mini-Reviews in Medicinal Chemistry Development of Anti-Viral Agents Using Molecular Modeling and Virtual Screening Techniques
Infectious Disorders - Drug Targets New Insights into HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Autophagy and Cell Death in Caenorhabditis elegans
Current Pharmaceutical Design Subject Index to Volume 1
Medicinal Chemistry Reviews - Online (Discontinued) Juvenile Dermatomyositis: Advances in Pathogenesis, Assessment, and Management
Current Pediatric Reviews The Biological and Clinical Activity of Anti-Malarial Drugs In Autoimmune Disorders
Current Rheumatology Reviews Kawasakis Disease, Acrodynia, and Mercury
Current Medicinal Chemistry Novel Approach to Treat Insulin Resistance, Type 2 Diabetes, and the Metabolic Syndrome: Simultaneous Activation of PPARα, PPARγ, and PPARδ
Current Diabetes Reviews Musculoskeletal Adverse Drug Reactions: A Review of Literature and Data from ADR Spontaneous Reporting Databases
Current Drug Safety Herb-Drug Interactions in Neurological Disorders: A Critical Appraisal
Current Drug Metabolism Cardiac and Muscular Involvement in Idiopathic Inflammatory Myopathies: Noninvasive Diagnostic Assessment and the Role of Cardiovascular and Skeletal Magnetic Resonance Imaging
Inflammation & Allergy - Drug Targets (Discontinued) Hepatic Manifestations in Juvenile Systemic Lupus Erythematosus
Recent Patents on Inflammation & Allergy Drug Discovery Muscle-Based Gene Therapy and Tissue Engineering for Cartilage and Bone Healing
Current Genomics Diffuse Alveolar Hemorrhage, A Potentially Life-Threatening Manifestation in Systemic Lupus Erythematosus and the Antiphospholipid Syndrome
Current Respiratory Medicine Reviews Sleep Related Disorders in the Elderly: An Overview
Current Respiratory Medicine Reviews